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ABSTRACT 
Parkinson’s disease (PD) is a common neurological disorder 
characterized by gait impairment. PD has no cure, and an 
impediment to developing a treatment is the lack of any accepted 
method to predict disease progression rate. The primary aim of 
this study was to develop a model using clinical measures and 
biomechanical measures of gait and postural stability to predict 
an individual’s PD progression over two years. Data from 160 PD 
subjects were utilized. Machine learning models, including 
XGBoost and Feed Forward Neural Networks, were developed 
using extensive model optimization and cross-validation. The 
highest performing model was a neural network that used a group 
of clinical measures, achieved a PPV of 71% in identifying fast 
progressors, and explained a large portion (37%) of the variance 
in an individual’s progression rate on held-out test data. This 
demonstrates the potential to predict individual PD progression 
rate and enrich trials by analyzing clinical and biomechanical 
measures with machine learning. 
Index Terms—Parkinson’s Disease, Prognosis, Machine 
Learning, Biomechanical Measures, Progression Rate 
 
 
1. INTRODUCTION 
Parkinson’s Disease (PD) is the second most common 
neurodegenerative disease after Alzheimer’s disease, with 
60,000 new PD diagnoses made annually resulting in a 
prevalence estimate by 2020 in the USA of 930,000 
people.1 PD is characterized by a progressive loss of 
dopaminergic neurons, resulting in resting tremor, limb 
stiffness, and bradykinesia, which often manifests early on 
with a reduction in arm swing amplitude when walking. 
The primary aim of this study was to develop a model using 
clinical and biomechanical gait and postural stability 
measures capable of identifying fast PD progressors with a 
high Positive Predictive Value (PPV). Achieving this goal 
will allow enrichment of future disease-modifying drug 
trials with fast progressors who are most likely to show 
detectable changes during a trial. Gait and postural stability 
measures were chosen as independent variables for our 
models because they have been previously found to be 
predictive of PD risk, disease severity, and PD diagnosis.2,3 
Baseline clinical measures were also investigated because 
of the potential they have to be predictive of PD 
progression rate. The most closely related study is by 
Latourelle et al.,4 where the predictive power of a 
composite biomarker set consisting of genetic, CSF, 
DaTscan, clinical and demographic features was examined. 
In contrast, our work examines the predictive power of 
gait, postural stability, clinical and demographic features.  
The main contributions of this study are: (1) the 
development of a predictive model of an individual’s PD 
progression rate that achieves a high PPV in identifying 
fast progressors suitable for enrichment of clinical trials to 
help expedite the development of a cure, and (2) the first 
models that indicate gait and postural stability measures are 
predictive of PD progression rate.  
 
2. MATERIALS 
Data were analyzed from 160 subjects with idiopathic PD 
followed longitudinally for 2 years. The subjects were part 
of the multi-year NIH-NINDS funded Parkinson’s Disease 
Biomarkers Program (PDBP).5 Patient demographics are 
shown in Table 1. Disease severity was measured using the 
Movement Disorder Society revision of the Unified 
Parkinson’s Disease Rating Scale (MDS-UPDRS). The 
MDS-UPDRS is a four-part assessment of PD severity as 
measured by a trained examiner. Part III of the assessment 
corresponds to the motor examination and involves 18 
Table 1 Demographics for 160 PD patients in the dataset 
Demographic Value 
Age 64.5 ± 9.5 
Men 54% 
Baseline MDS-UPDRS part III score 16.0 ± 7.9 
2 year MDS-UPDRS part III score 18.2 ± 7.6 
On any PD medication 84% 
On levodopa 63% 
 
 
 
sections which are each scored on a scale from 0 (normal) 
to 4 (severe). Examples of sections include speech, facial 
expression, and gait examinations. Some sections have 
subsections for each hand (LH, RH) or for each upper and 
lower extremity (RUE, LUE, RLE, LLE). The total part III 
score has a range of 0 to 132. For this dataset, a trained and 
MDS certified examiner with eight years of prior 
experience conducted the assessments. 
 
3. METHODS 
Three targets for regression were tested individually in the 
following experiments: (1) total part III score at 24 months, 
(2) 24 months-baseline change in part III, and (3) percent 
change in part III measured as (24 months-
baseline)/baseline. These targets were chosen as it was not 
known a priori whether absolute severity or a change in 
severity is a more predictable target. The progression of the 
total part III score over two years is shown in Fig. 1. A 
paired t-test revealed that the mean score at 24 months was 
statistically different from that at baseline (p < 0.01) while 
the mean scores at previous visits were not, indicating that 
24 months is the first point at which significant progression 
is observed. The variability of scores across subjects 
exemplifies PD heterogeneity and indicates the challenging 
nature of the task of predicting individual progression rate.  
 
For the gait and posture measures, subjects performed two 
tasks while using the APDM Mobility Lab system which 
uses six inertial sensors to quantify limb and torso motion. 
The tasks were: 
1. The instrumented Timed-up-and-go (iTUG) test: 
subjects stand up from a chair, walk 6 meters, 
turn, walk back and sit down. 
2. The instrumented Sway (iSway) test: subjects 
stand still with their feet a set distance apart and 
their hands across their chests for 30 seconds. 
Three runs of iTUG and iSway were conducted at each visit 
and the median values of 148 summary statistics were 
utilized. Examples of measures include gait speed, step 
duration, stride length, arm swing velocity, and sway area. 
Clinical measures were used including: age, gender, 
baseline MDS-UPDRS part III subscores, Levodopa 
Equivalent Daily Dose (LEDD), and MOntreal Cognitive 
Assessment (MOCA) score.  
 
3.1 Feature set construction and feature selection: 
Seven sets of features were compared for predictive power, 
encompassing different combinations of iTUG and iSway 
summary statistics, clinical measures, and additional 
derived features (Fig. 2). These included a set with the 
baseline iTUG and iSway measures (which we refer to as 
BaseG, short for baseline gait) and a set of derived features 
with the difference between iTUG and iSway measures at 
6 months and at baseline (DeltaG, i.e. delta gait), which 
capture progression of motor symptoms. Asymmetric 
presentation of motor dysfunctions in PD has shown to be 
an important marker of PD severity,6 so asymmetry 
measures on the 22 lateralized variables in baseline 
(AsyBaseG) and 6 months-baseline iTUG and iSway 
(AsyDeltaG) were computed with the formula                              
1 − ௅௘௙௧ ௠௘௔௦௨௥௘
ோ௜௚௛௧ ௠௘௔௦௨௥௘
. All of these iTUG and iSway measures 
were combined in feature set AllG, i.e. all gait measures. 
Clinical measures were considered by themselves (Clin) 
and in combination with all iTUG and iSway measures 
(AllGClin, i.e. all gait and clinical measures). Feature 
selection was conducted on the training partitions by 
dropping one member of each pair of highly intercorrelated 
features (Pearson’s r > 0.8) to minimize feature 
redundancy.  
3.2 Data partitioning and model training: XGBoost and 
Feed Forward Neural Network (NN) models were chosen 
as they are two of the most powerful models that 
consistently win machine-learning competitions for 
Figure 1 Progression of MDS-UPDRS part III score across 24 
months. Individual subjects plotted as grey lines. Mean and 
standard deviation across subjects plotted in red. Zoomed view 
on right shows increasing severity longitudinally. 
Figure 2 Feature set combinations explored. Number of features 
in each set indicated in parentheses. Abbreviations for feature 
sets in column headers.  
 
 
structured and unstructured data and have shown high 
performance in a wide range of tasks.7 Mean-squared-error 
loss was used to train the NNs. Model performance was 
evaluated using the R2 score, i.e., the coefficient of 
determination. The dataset was partitioned using nested K-
fold cross validation with 3 inner and 3 outer folds. In each 
outer fold, mean R2 across the held-out partitions of the 
inner folds was used to rank model performance and the 
model with the highest mean R2 was selected for evaluation 
on the held-out partition of the outer fold. The mean test 
performance over the held-out partitions in the 3 outer 
folds represents final model performance. Stratified k-fold 
partitioning was used to ensure representative target 
distributions across splits and appropriate model training 
and evaluation. 
 
3.3 Hyperparameter optimization and model selection: 
To identify optimal model hyperparameters in an unbiased 
manner, a random search of 1000 hyperparameter 
configurations for XGBoost and 300 configurations for 
NNs was conducted. Fewer configurations were searched 
for NNs due to computational requirements. The 
hyperparameter dimensions and ranges searched are shown 
in Table 2. The best-performing hyperparameter 
configurations were selected based on mean R2 across the 
inner cross-validation folds, and the model’s performance 
is evaluated as the mean R2 evaluated on the held-out test 
splits. Hyperparameter vs. performance plots [not shown] 
confirmed that sufficient ranges of the hyperparameters 
was searched such that the local maxima of performance 
were found. 
3.4 Feature importance: To reveal what the NNs learned, 
feature permutation importance was used to compute 
feature importance. Each feature in the held-out test set was 
randomly permuted 100 times and the decrease in R2 was 
measured, with a greater mean decrease reflecting greater 
importance.  
 
4. RESULTS 
The mean test R2 performances of the best models on each 
feature set × target combination are shown in Fig. 3. NNs 
outperformed XGBoost models in every case. The feature 
set Clin, which used only the clinical measures, achieved 
the highest R2 across all prediction targets and model 
categories. Using this feature set, 37% of the variance was 
explained in the percentage change MDS-UPDRS part III 
score. Given that predicting progression rate is a difficult 
problem as indicated by the large standard deviation of ± 8 
points in the progression rate across subjects, explaining 
nearly 40% of the variance in progression rate using our 
model is a significant finding. This result is comparable to 
the 41% validation performance achieved by Latourelle et 
al.,4 and has the added strength that our evaluation is on 
held-out test data while theirs was on validation data which 
typically inflates the result. Our model achieved a PPV of 
71% in identifying fast progressors, defined as having a 
20% or more increase in MDS-UPDRS part III score from 
baseline (top 50% of the cohort).  
This is also the first study to show gait and postural stability 
measures to be predictive of PD progression. Three of the 
gait and postural stability feature sets explained 10% or 
more of the variance in the 2 year MDS-UPDRS part III 
Table 2 Hyperparameter ranges explored for each model. 
XGBoost 
Number of estimators: [10, 1000] 
Maximum depth: [5, 50] 
L1 regularization term: (0, 1) 
L2 regularization term: (0, 1) 
Learning rate: [0.0001, 0.4] 
 
 
Feed Forward Neural Network 
Layers: [1, 5] 
Chance to taper: 50% 
Taper size: {0.2, 0.5} 
Dropout: [0.1, 1.0] 
Activations: {ReLU, ELU, LeakyReLU, PReLU, 
tanh, sigmoid} 
Number of neurons: {16, 32, 48, 64, 80, 96, 112, 
128} 
Learning rate: [0.0001, 0.005] 
Optimizer: Nadam 
 
  
Figure 3 Mean test R2 performances of best models on 
each feature-target combination. Feature sets are 
shown on the x-axis and targets are shown on the y-
axis. The color bar indicates R2, with brighter green 
indicating better performance and black indicating 0 or 
negative R2 performance.  
 
 
score. Feature set AllG, which included all the derived gait 
and postural stability measures, explained 21% of the 
variance.  
The 15 most important features learned by NNs on sets 
Clin and AllG are shown in Fig. 4. The MDS-UPDRS part 
III RUE rigidity subscore, total score, and Right Hand 
Finger Tapping subscore were the three most important 
features for predicting percent change (Fig. 4A). In the 
AllG feature set, the (6 months-baseline) iTUG asymmetry 
values ranked high in feature importance, with the iTUG 
gait stride velocity asymmetry change as the most 
important for predicting the 2 year score (Fig. 4B). 
 
 
5. DISCUSSION 
The best model performance was obtained using clinical 
measures to predict the 2 year percent change MDS-
UPDRS part III score with an NN. The model explained 
37% of the variance in the target, with a PPV of 71% in 
identifying fast progressors. Thus, the model may be useful 
in enriching disease-modifying drug trials with fast 
progressors. Similar to Latourelle et al.,4 baseline 
movement scores from Clin are found to be among the 
most important features for predicting future progression 
rate.  
Further, this is the first study to show that gait and postural 
stability measures have predictive power for PD 
progression. The (6 months-baseline) iTUG asymmetry 
values ranked high in feature importance, indicating that 
the progression of asymmetric aspects of gait impairments 
are especially important for predicting PD progression. 
This demonstrates the prognostic value that can be 
provided by improved measurements of motor disability in 
PD subjects. While the gait and postural stability measures 
alone in AllG performed modestly (R2=0.21), their 
performance was bolstered by the inclusion of clinical 
measures in AllGClin (R2=0.30). However, this 
performance boost was not additive, suggesting that the 
feature sets have collinearities and measure similar aspects 
of PD progression.  
The primary limitation of this study is that a single dataset 
was used. Though the dataset was fairly large (N=160 
subjects) and rigorous cross-validation was performed 
including a held-out test set not used for training or model 
selection, a replication study on an independent dataset 
would further confirm our findings. Fortunately, other 
datasets are becoming available and replication of our 
model’s performance on these datasets is the subject of our 
ongoing research. Additional future studies are planned to 
increase predictive power using other methods to derive 
features from the iTUG and iSway sensor data. Such 
deeper analysis may enable even more prognostic 
applications. 
6. CONCLUSION  
The main contributions of this study include the 
development of a predictive model of an individual’s PD 
progression rate that achieves a 71% PPV in identifying 
fast progressors, which is suitable to enrich clinical trials 
to help expedite the development of a cure for PD. This 
work reaffirms the importance of clinical measures in 
predicting PD progression and suggests the potential for 
gait and postural stability measures as a predictive tool. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Mean feature importances of the top 15 
features learned by the best performing NNs. A) Top 
features using feature set Clin to predict the percent 
change in MDS-UPDRS part III and B) Top features 
using feature set AllG to predict 2 year MDS-UPDRS 
part III score. Error bars represent the standard 
deviation of the feature importance across the outer 
A)    B) 
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